Hydroxychloroquine (HCQ) reverses anti-PD-1 immune murine checkpoint blockade: TCF1 as a marker in humans for COVID-19 and HCQ therapy

Janna Krueger, Francois Santinon, Alexandra Kazanova, Mark Issa, Bruno Larrivee, Catalin Milhalcioiu, Christopher E. Rudd
doi: https://doi.org/10.1101/2020.09.29.20193110

Article usage

Article usage: September 2020 to November 2024

AbstractFullPdf
Sep 2020244021
Oct 20208070137
Nov 202084044
Dec 202089041
Jan 202169031
Feb 202190417
Mar 2021110721
Apr 2021133311
May 202111307
Jun 2021198419
Jul 202148312
Aug 202146626
Sep 202144116
Oct 202154235
Nov 202134822
Dec 202134113
Jan 202228710
Feb 20222628
Mar 20222013
Apr 20222224
May 202237511
Jun 20221748
Jul 20222313
Aug 20222049
Sep 202232410
Oct 20222819
Nov 20222146
Dec 20222129
Jan 20232046
Feb 20231759
Mar 20231511
Apr 20232123
May 20231218
Jun 2023956
Jul 20231115
Aug 202319137
Sep 20231367
Oct 202319713
Nov 202319132
Dec 2023922
Jan 20241207
Feb 2024868
Mar 202415424
Apr 20241768
May 20241315
Jun 20241687
Jul 2024525
Aug 20241269
Sep 20242259
Oct 20241355
Nov 20241725
Back to top
Posted September 30, 2020.
Download PDF

Supplementary Material

Data/Code
Email
Hydroxychloroquine (HCQ) reverses anti-PD-1 immune murine checkpoint blockade: TCF1 as a marker in humans for COVID-19 and HCQ therapy
Janna Krueger, Francois Santinon, Alexandra Kazanova, Mark Issa, Bruno Larrivee, Catalin Milhalcioiu, Christopher E. Rudd
medRxiv 2020.09.29.20193110; doi: https://doi.org/10.1101/2020.09.29.20193110
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area